Chester A Metcalf 3rd
Overview
Explore the profile of Chester A Metcalf 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Metcalf 3rd C, Svenson S, Hwang J, Tripathi S, Gangal G, Kabir S, et al.
J Med Chem
. 2019 Oct;
62(21):9541-9559.
PMID: 31593466
Novel nanoparticle-drug conjugates (NDCs) containing diverse, clinically relevant anticancer drug payloads (docetaxel, cabazitaxel, and gemcitabine) were successfully generated and tested in drug discovery studies. The NDCs utilized structurally varied linkers...
2.
Zhang J, Chan A, Lippa B, Cross J, Liu C, Yin N, et al.
Bioorg Med Chem Lett
. 2017 Mar;
27(8):1670-1680.
PMID: 28302397
The emergence and spread of multidrug-resistant (MDR) Gram negative bacteria presents a serious threat for public health. Novel antimicrobials that could overcome the resistance problems are urgently needed. UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase...
3.
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design
Cross J, Zhang J, Yang Q, Mesleh M, Romero J, Wang B, et al.
ACS Med Chem Lett
. 2016 Apr;
7(4):374-8.
PMID: 27096044
The ATPase subunit of DNA gyrase B is an attractive antibacterial target due to high conservation across bacteria and the essential role it plays in DNA replication. A novel class...
4.
Zhang J, Yang Q, Romero J, Cross J, Wang B, Poutsiaka K, et al.
ACS Med Chem Lett
. 2015 Oct;
6(10):1080-5.
PMID: 26487916
Antibacterials with a novel mechanism of action offer a great opportunity to combat widespread antimicrobial resistance. Bacterial DNA Gyrase is a clinically validated target. Through physiochemical property optimization of a...
5.
Zhang J, Yang Q, Cross J, Romero J, Poutsiaka K, Epie F, et al.
J Med Chem
. 2015 Oct;
58(21):8503-12.
PMID: 26460684
The emergence and spread of multidrug resistant bacteria are widely believed to endanger human health. New drug targets and lead compounds exempt from cross-resistance with existing drugs are urgently needed....
6.
OHare T, Shakespeare W, Zhu X, Eide C, Rivera V, Wang F, et al.
Cancer Cell
. 2009 Nov;
16(5):401-12.
PMID: 19878872
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch...
7.
Boyce B, Xing L, Yao Z, Yamashita T, Shakespeare W, Wang Y, et al.
Clin Cancer Res
. 2006 Oct;
12(20 Pt 2):6291s-6295s.
PMID: 17062716
Src tyrosine kinase was the first gene product shown to have an essential function in bone using recombinant DNA technology after its expression was knocked out in mice approximately 15...
8.
Han L, Landen C, Trevino J, Halder J, Lin Y, Kamat A, et al.
Cancer Res
. 2006 Sep;
66(17):8633-9.
PMID: 16951177
Src, a nonreceptor tyrosine kinase, is a key mediator for multiple signaling pathways that regulate critical cellular functions and is often aberrantly activated in a number of solid tumors, including...
9.
Boyce B, Xing L, Yao Z, Shakespeare W, Wang Y, Metcalf 3rd C, et al.
Ann N Y Acad Sci
. 2006 Jul;
1068:447-57.
PMID: 16831942
Understanding of the regulation of bone catabolism has advanced significantly over the past two decades with the identification of key enzymes that regulate osteoclast formation, activation, and survival following their...
10.
Azam M, Nardi V, Shakespeare W, Metcalf 3rd C, Bohacek R, Wang Y, et al.
Proc Natl Acad Sci U S A
. 2006 Jun;
103(24):9244-9.
PMID: 16754879
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in patients with chronic myelogenous leukemia. Many mutations favor active kinase conformations that preclude imatinib binding. Because...